(“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human ...

Muscarinic receptors are important drug targets in psychosis ... effects while avoiding the unwanted activation of M2 and M3 and its associated side effects. Our selective muscarinic agonist ...

Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic ...

These novel drug candidates have been designed to deliver improved therapeutic effects while avoiding the unwanted activation of M2 and M3 and its associated side effects. Our selective muscarinic ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions to ...

Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat ...

The precision of the PK match between the muscarinic agonist and antagonist was designed to facilitate dose escalation of ML-007, enhance the tolerability profile by effectively neutralizing ...

This clinical brief is supported by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of ...